Anders Albåge is a Senior Consultant cardiac surgeon and Associate Professor at the University Hospital, Uppsala, Sweden. From 2016 to date, he is Director for valvular surgery in carcinoid heart disease at Uppsala University Hospital. Previously, he worked as a Consultant cardiac surgeon at the Karolinska University Hospital, Solna/Stockholm and Huddinge University Hospital, Stockholm. He completed his dissertation entitled "surgical treatment of atrial fibrillation: aspects of the Maze operation" in 2003. In 2000, he was a clinical fellow at the Department of Cardiovascular Surgery at Toronto General Hospital, Toronto, Canada.
Valentina Ambrosini is Associate Professor at University of Bologna, Italy, in the Department of Experimental Diagnostic and Specialized Medicine (DIMES), scientific sector MED/36-Diagnostic Imaging, and she is a nuclear medicine physician at Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna. She is a certified specialist in both respiratory and nuclear medicine and belongs to the NET Bologna multidisciplinary team, an ENETS Center of Excellence (CoE). She is a member of the ENETS Advisory Board, an ESMO faculty staff member for neuroendocrine and endocrine neoplasms and CUP, is a member of the ITANET scientific committee and the Editorial Board for the Journal of Nuclear Medicine and of Cancers. Professor Ambrosini is a reviewer for JNM and EJNMMI. She has authored 121 scientific articles in peer-reviewed journals (h-index = 38, total citations = 4,403). She has worked on the European Association of Nuclear Medicine (EANM) guidelines for PET/CT use in neuroendocrine tumors (version 2010, 2017) and the Italian medical oncology guidelines on neuroendocrine tumors.
Leonidas Apostolidis heads the Clinical Cancer Research Program (CP) “Neuroendocrine” at the National Center for Tumor Diseases (NCT) Heidelberg, Germany. He studied medicine at Heidelberg University, Germany, completed his clinical training at Heidelberg University Hospital, and earned his doctorate at the German Cancer Research Center (DKFZ). He is a senior physician at the Department of Medical Oncology at the NCT Heidelberg, and also directs the oncologic division of the Salem Hospital Heidelberg. Dr Apostolidis is member of the European Society of Medical Oncology (ESMO), European Neuroendocrine Tumor Society (ENETS) and German Society of Nutritional Medicine (DGEM). He is a board-certified specialist in internal medicine, haematology, oncology, palliative medicine, and nutritional medicine, and has obtained the ESMO examination certificate for medical oncology. His scientific and clinical focus lies on NETs, hepatobiliary tumors and sarcoma, especially in the fields of molecular stratification for novel therapeutic approaches and immunotherapy.
Detlef K Bartsch is Professor and Chairman of the Department of Visceral, Thoracic and Vascular Surgery at the Philipps-University Marburg, Germany. He has 25 years’ experience in the field of endocrine and pancreatic surgery, especially in GEP-NETs and MEN-1. He is the surgical partner of the ENETS Center of Excellence (CoE) at the Marburg University Hospital. He was President of the German Society of Endocrine Surgeons from 2014 until 2017. Professor Bartsch has published more than 280 publications in peer-reviewed journals and serves on the ENETS Executive Committee.
Eric Baudin, Associate Professor, is Head of the Endocrine Oncology Unit at the Institut Gustave Roussy, Villejuif, France. His research areas include the diagnosis, treatment, and follow-up of patients with endocrine tumors. Dr Baudin has served on the Advisory Board to ENETS, ENSAT and ESMO. He has published widely on the management of endocrine tumors. He is head of coordination for the French Endocrine Tumor Network (from 2019 to date) and is currently President of the French Group of Endocrine Tumors (2017 - 2019). He became a member of the ENETS Executive Committee in 2020.
Emily Bergsland, MD, is a medical oncologist at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, USA, and specialises in gastrointestinal malignancies. She is a Professor of Medicine and Director of the Center for Neuroendocrine Tumors at UCSF. In addition, Dr Bergsland serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. She leads a clinical-translational research programme focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging, and clinical outcomes.
Ricardo Blázquez Encinas-Rey is a PhD student in the biomedicine field at the University of Córdoba (UCO), Spain. He graduated in 2018 in biochemistry at the UCO. He completed his degree project at the Hormones and Cancer Group of the Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), obtaining the highest qualification. In 2018, he received a grant from the Ministry of Education to collaborate in the Department of Cell Biology, Physiology, and Immunology, and began his research activity while carrying out his master's studies in translational biomedical research. In 2019, he received a competitive grant to begin his PhD studies under the direction of Dr Justo P. Castaño, studying RNA metabolism dysregulation in neuroendocrine tumors and pancreatic adenocarcinoma.
Lisa Bodei is a nuclear medicine physician and Director of Targeted Radionuclide Therapy in the Memorial Sloan Kettering Cancer Center, New York, USA. She graduated from the Medical University of Pisa and earned her Doctor of Medicine degree in 1995 and remained at Pisa University as a Resident in Nuclear Medicine at the School of Specialization until 1999. In 2009, she was awarded a PhD (magna cum laude) from the Department of Nuclear Medicine and Molecular Imaging, University of Groningen, the Netherlands, for her work in peptide receptor radionuclide therapy using somatostatin analogues. Her main research interests include theragnostics, particularly peptide receptor radionuclide therapy with somatostatin, bombesin, and PSMA analogues for diagnosis and therapy, and translational research applied to radiopeptide therapy of neuroendocrine tumors. She has authored more than 160 articles in peer-reviewed journals and published 8 book chapters. She currently serves as one of the associate editors of the Journal of Nuclear Medicine, section editor for Molecular Imaging and Therapy of Clinical Imaging on the editorial boards of several scientific journals, including the Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.
Mette Borre is a clinical dietician at the Department of Hepatology and Gastroenterology, an ENETS Center of Excellence (CoE), at Aarhus University Hospital, Denmark. She is also a teacher at VIA University College, Aarhus, Denmark, and advisor to the Danish National Board of Health on the panel for the acceptance of nutritional supplements and tube feeding. She has a special interest in the nutritional treatment of patients with neuroendocrine tumors. Mette has co-authored two scientific articles on nutritional status and nutritional risk for patients with neuroendocrine tumors as well as the use of biologically based complementary medicines in patients with neuroendocrine tumors in the Scandinavian Journal of Gastroenterology.
Catherine Bouvier is a nurse, CEO of Neuroendocrine Cancer UK, and current President of INCA, who has dedicated the past twenty years of her career to improve the care and outcomes for neuroendocrine cancer (NC) patients. Her passion is to set and help implement eight strategic priorities in the NC field: the protection of NC services; improving impact and outcomes for patients who follow a less common pathway; establishing patient experience as being on a par with clinical effectiveness and safety; the provision of standardised useful and accurate patient information; significant increase in research, education and awareness in neuroendocrine cancer; ensuring commissioning processes are fit for purpose; and, that the NC community truly collaborates nationally and globally to ensure standardised care for all NC patients.
Maria Luisa Brandi is Full Professor of Endocrinology and Metabolic Diseases at the University of Florence, Italy, and directs the regional programme on Hereditary Endocrine Tumors in the Bone Metabolic Unit at the University of Florence. She obtained her master’s degree in 1977, was board certified in endocrinology in 1980, and obtained her PhD degree in cell biology in 1987. Professor Brandi owns 7 patents, and has published more than 600 papers in peer-reviewed journals as well as 200 book chapters. She was the President of the Italian Society of Osteoporosis, and is a member of the Scientific Committee of the IOF, General Secretary of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and President Fondazione Italiana per la Ricerca sulle Malattie dell’Osso.
Jaume Capdevila is a medical oncologist at Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, an ENETS Center of Excellence (CoE). Since early 2013 he also leads the gastrointestinal and endocrine tumor unit at Teknon Cancer Institute. He obtained his medical degree in the University of Lleida, in Catalonia, Spain. In 2000 and 2001 he held a fellowship in the Department of Biochemistry and Molecular Biology at the University of Lleida. Between 2002 and 2006, he specialised in medical oncology at the Santa Creu i Sant Pau University Hospital, Barcelona. He is involved in research and treatment of patients with gastrointestinal cancer and endocrine tumors as well as in early-drug development. He has published over 90 articles in peer-reviewed journals and several book chapters. He is an active member of several oncology societies (ASCO, ENETS, EORTC, SEOM, TTD, GEMCAD, GETNE, and GETHI) and actively participates in national and international trials. He is member of the advisory board of the European Neuroendocrine Tumor Society (ENETS), Secretary and Treasurer of the Spanish Task Force for neuroendocrine tumors (Grupo Español de Tumores Neuroendocrinos, GETNE) and funding member and Treasurer of the Spanish Task Force Group for Research in Orphan and Rare Tumors (Grupo Español de Tumores Huérfanos e Infrecuentes, GETHI). He is also the medical oncologist member of the Thyroid Cancer Working Group within the Spanish Society of Endocrinology and Nutrition (SEEN).
Justo P. Castaño is Professor of Cell Biology at the University of Córdoba and Head of the Hormones and Cancer group at the Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Spain. His team investigates the cellular and molecular basis of neuroendocrine tumors (NETs), pancreatic adenocarcinoma, pituitary tumors and other cancers, exploring the emerging (patho)physiologic/oncogenic role of alternative splicing and RNA biology dysregulation, including aberrant variants of neuropeptides (e.g. In1-ghrelin) and receptors (e.g. SST5TMD4). He is currently a member of the ENETS Advisory Board, governing boards of GETNE (Spanish Neuroendocrine Tumors Group), and past Acting Secretary of European Society of Endocrinology (ESE) from 2010 - 2014, and member of the governing board of SEEN (Spanish Endocrinology and Nutrition Society; 2016-2019). He has published 200 peer-reviewed articles, directed 18 doctoral thesis and received the SEEN Prize “Research Career in Neuroendocrinology”.
David Chan is a medical oncologist at Royal North Shore Hospital and an academic at the University of Sydney, Australia. After completing his specialty training, he undertook a NET fellowship at Sunnybrook Health Sciences Centre, Toronto. He has recently completed his PhD investigating the role of PET as biomarkers in NENs and received an Australian government grant from 2020 - 2024 to further this research. He has authored more than 50 peer-reviewed research articles with a particular interest in NEN imaging and therapy as well as systematic reviews. He was elected the chair of the NET committee for COSA in 2019.
Aman Chauhan is a board-certified medical oncologist at the University of Kentucky’s Markey Cancer Center, USA. Dr Chauhan earned his medical degree from the Kasturba Medical College in Manipal, India. He then completed a dual residency in internal medicine and paediatrics at Louisiana State University in New Orleans. He completed a fellowship in haematology and oncology at the University of Kentucky with a focused training on neuroendocrine tumor (NETs). Additionally, Dr Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) which focused on training early career physician-scientists in designing clinical trials and clinical research projects. His clinical interests include the treatment of NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small cell carcinoma. Dr Chauhan is the Director of NET Theranostics at Markey. He leads various investigator-initiated Phase I and Phase II clinical trials and is currently funded by NCI CTEP to study DNA PK inhibitors in preclinical NET models. Dr Chauhan has co-authored more than 50 PubMed indexed manuscripts.
Jie Chen is Deputy Director of the Department of Gastroenterology, the First Affiliated Hospital, Sun Yat-Sen University, China. Her main area of interest is neuroendocrine tumors. As one of the pioneer experts for NETs in China, she founded the first Multidisciplinary Care Team for NETs in China in 2011 and the Chinese Study Group for Neuroendocrine Tumors (CSNET) in 2015. Her major areas of research interest are the diagnostic and therapeutic strategies of NETs. She has published high-quality peer-reviewed papers in NETs field over the past ten years. She has been a member of the ENETS Advisory Board since 2015. She also joined the editorial board of Journal of Pancreatology since 2018. She served as Associate Editor of Neuroendocrinology from 2019 to 2020.
Emanuel Christ is Associate Professor in Internal Medicine, Endocrinology, Diabetology and Metabolism and an approved adult general internist and endocrinologist/diabetologist. He works at the University Hospital of Basel, Switzerland, as the Head of Interdisciplinary Endocrinology. His main area of research focuses on functional/molecular imaging techniques in patients with pituitary disease, metabolic disorders and neuroendocrine tumors. Since 2003, he continuously acquired research grants, e.g. from the Swiss National Science Foundation. Besides his main research focus, he is a Co-founder and the actual president of SWISSNet, a national prospective registry for neuroendocrine tumors (established in 2009) and includes more than 1,700 patients with a median follow-up of more than three years. He participated in the Frascati Consensus Conferences in 2005/2006 and is a member of the ENETS Advisory Board since 2019.
Anne Couvelard is Professor of Pathology at Université de Paris and Head of the Department of Pathology in Beaujon and Bichat Hospitals, Paris, France. Her main topics of research are pancreatic and neuroendocrine oncogenesis, pathology and molecular markers. She is a member of ENETS since 2004, joined the ENETS Advisory Board member in 2015, and became an ENETS Executive Committee member in 2018. She is a member of the French pathological network for neuroendocrine tumors « TENpath » since 2011, and was involved in the 2017 and 2019 WHO classifications of tumors of endocrine organs and of the digestive system. She has published more than 300 papers in international journals and is a reviewer for journal in the fields of pathology, oncology gastroenterology and endocrinology.
Jerome Cros is a Professor of Pathology at the Beaujon Hospital-Université de Paris, Clichy-France, France, an ENETS Center of Excellence (CoE) and the largest French pancreatic surgical center. He is in charge of pancreatic pathology and leads a research group dedicated to (i) the study of pancreatic tumors, focusing on tumor heterogeneity and chemotherapy-induced clonal selection, (ii) the development of innovative tools (AI, MALDI imaging, etc.), and (iii) to subtype tumors according to their molecular profile.
Talya L. Dayton is a postdoctoral fellow in the lab of Hans Clevers at the Hubrecht Institute in Utrecht, the Netherlands. In her research, she uses organoids to study neuroendocrine neoplasms. In 2016, Talya received a Ph.D. from the Massachusetts Institute of Technology (MIT) for her work in the lab of Tyler Jacks using mouse models to study pyruvate kinase isoforms in development and cancer. For her graduate work, Talya was awarded fellowships from the National Science Foundation and the Department of Defence. Talya is the recipient of an EMBO and a Marie Curie Individual Postdoctoral Fellowship.
Timm Denecke is a radiologist and nuclear medicine specialist and is currently Chair of Radiology at Leipzig University Medical Center, Leipzig, Germany. He became a member of the ENETS Advisory Board in 2020. Professor Denecke has authored and co-authored more than 240 papers in peer-reviewed scientific journals and more than 3,800 citations. Before moving to his new position in Leipzig, he worked at the Charité – Universitätsklinikum in Berlin, Germany.
Clarisse Dromain is currently the head of digestive and oncologic imaging in CHUV University Hospital of Lausanne, Switzerland. She graduated from medical school at the University of Paris VI, France, in 1992. In 2015, she completed a PhD and was nominated Associate Professor at UNIL in 2018 and Full Professor at UNIL in 2020. Her major research interests include gastrointestinal, in particular endocrine and peritoneal tumor imaging. She is also involved in numerous clinical trials for her expertise in assessment of treatment response. Throughout her career, Clarisse has been a significant contributor to research and education in radiology and its application in oncology. These contributions include co-authoring 143 peer-reviewed publications, including those relating to the imaging of NETs, and has been invited more than 70 times to lecture at an international level. In addition, she is a reviewer for renowned journals such as JCO, Radiology and European Radiology.
Sugandha Dureja, MD, is a Nuclear Medicine physician with a special interest and training in theragnostics for NETs. She is the Founder of CNETS India, a patient advocacy group for NEN patients in the Indian subcontinent, which is also a member of the International Neuroendocrine Cancer Alliance (INCA).
Stéphane Ederhy is a cardiologist and practitioner at the Saint Antoine Hospital in Paris, France. He currently leads the French working group on cardio-oncology. Recognised for his specialisation in medical imaging and cardio-oncology, Dr Ederhy participates in the development of new technologies and focuses his research on thromboembolic risk in atrial fibrillation, the assessment of stroke without cause, and the imaging and biomarker screening of cardiotoxicity induced by anticancer drugs.
Aurelie Fabre is a Consultant Histopathologist at the Department of Histopathology, St Vincent's University Hospital, Dublin, Ireland, and Clinical Professor University College Dublin (UCD) Medical School. She has a special interest in thoracic pathology. She is the Lead in Pulmonary Pathology at St Vincent's University Hospital and runs/participates in weekly MDTs, cancer and non-cancer including interstitial lung diseases and rare/cystic lung diseases. She graduated from Trinity College Dublin in 1996, obtained a master’s degree in Medical Sciences in Pathology at University College Dublin in 1998, and went on to train in histopathology in Paris and London, where she passed her MRCPath in 2002. She then completed a PhD thesis on the pathogenesis of lung fibrosis at the same time and completed a fellowship in Thoracic Pathology at Bichat Hospital, Paris, in 2007 and 2012. Her main interests include interstitial lung diseases, lung cancer, heart and lung transplant pathology, and cardiac/cardiovascular pathology. In terms of research, she provides expertise in tissue and cell morphology, image analysis, animal models and immunohistochemistry. She is the Founder/Director of the Research Pathology Core technology at the UCD Conway Institute, integrating Research Immunohistochemistry and Digital Pathology.
Antongiulio Faggiano is Associate Professor of Endocrinology at the Department of Experimental Medicine, Sapienza University of Rome, Italy. He was a post-graduate fellow in endocrinology in 2002 at the Federico II University of Naples, obtained a European University Research Diploma in Clinical Oncology in 2003 at the Paris-SUD University, a PhD in Molecular Oncology and Endocrinology in 2007 in Italy and France. Professor Faggiano was coordinator of the ENETS Center of Excellence (CoE) of Naples from 2013 - 2018. Since 2018 he is a member of the Advisory Board of both ENETS and the Italian Society of NETs. He has authored more than 200 full papers in international peer-reviewed journals (h-index 41). He is coordinator of Unit for an Italian Project of National Relevant Interest (PRIN 2017) on NEN. His research interests include neuroendocrine neoplasms and endocrine tumors with a particular focus on therapy with somatostatin analogues and hereditary endocrine syndromes (MEN-1).
Massimo Falconi is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, Milan, ltaly. He studied medicine at the University of Verona, specialising in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects in such diverse places as Germany, Spain, Ecuador, and Japan. He is also a member of many medical societies and currently serves on executive committee of IAP and on the Advisory Board of ENETS. He has written more than 300 peer-reviewed articles and reviews articles for numerous of journals. Professor Falconi serves as Associate Editor for the section on pancreas and neuroendocrine tumors for Digestive and Liver Disease, the official journal of the ltalian and French gastroenterological societies. He has an impact factor calculated on the basis of JCR 2014 of more than 1,500 and his h-index on Scopus is 61.
Nicola Fazio is the Director of the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors and Director of the programme in Digestive and Neuroendocrine Tumors at the European Institute of Oncology (IEO, IRCCS) in Milan, Italy, since 1995. Since 2015 he is head of the IEO ENETS Center of Excellence for GEP NETs. He served as ESMO Faculty Coordinator for Neuroendocrine, Endocrine and CUP from 2016 - 2019. He was Chair of the ESMO NEN Preceptorship from 2017 - 2018 and was invited to be Chair again in 2019. He was also asked to be chair of the ESMO NEN Advanced Course in 2019. Since 2013, he is Coordinator of the Italian (AIOM/ITANET) neuroendocrine neoplasms guidelines. Dr Fazio is an ENETS member, was Advisory Board Chairman since 2019 and member of the ENETS Advisory Board since 2015. Since 2020 he is member of the ENETS Executive Committee. He graduated in 1988 from the Faculty of Medicine and Surgery at the University of L’Aquila, Italy. In 1993, he specialised in internal medicine and in 2003, in oncology. In 2013, he gained a PhD in Digestive Oncology.
Uli Fehrenbach is a subspecialised diagnostic and interventional Radiologist at the Charité University Medicine Berlin, Germany. His research areas focus on abdominal radiology in oncologic diseases with a special interest in hepatobiliary magnetic resonance imaging and neuroendocrine neoplasms. He is the radiological lead of the multidisciplinary cancer conference for neuroendocrine tumors at the Charité and is involved in the diagnostics and interventional radiological treatment of the ENETS Center of Excellence’s patients.
Pier Luigi Filosso, M.D., is Associate Professor of Thoracic Surgery at the Medical Faculty of the University of Torino, Italy. He is also Chair of the European Society of Thoracic Surgeons (ESTS) Lung Neuroendocrine Tumors Working Group; he was Secretary of the International Thymic Malignancy Interest Group (ITMIG). He is active Member of the most important international ihoracic scientific societies: The Italian Society of Thoracic Surgery (SICT); the European Neuroendocrine Tumor Society (ENETS; the European Society of Thoracic Surgeons (ESTS); the International Association for the Study of Lung Cancer (IASLC). His fields of interest are: Thoracic Oncology, Lung and Thymic NETs, Surgical Treatment of Lung, Mediastinal and Pleural Neoplasms, Emphysema and Management of Thoracic Trauma. He published 190 papers in International peer reviewed journals on Thoracic Oncology issues.
Wolf H. Fridman is Professor Emeritus of Immunology at the Université de Paris, France. He received his MD and PhD degrees from University of Paris. After 10 years in the laboratory headed by Jean Dausset, he created his own laboratory at the Cancer Research Institute in Villejuif in 1976, then moved to Institut Curie in 1983 and Hopital Georges Pompidou in 2000. In 2007 he created and directed the Cordeliers Research Centre. Dr Fridman’s research interests focus on the role of the immune system in controlling human tumors and the biological functions of receptors for IgG antibodies, both through basic and translational approaches.
Rocio Garcia-Carbonero is a Consultant in medical oncology at Hospital Universitario Doce de Octubre, Madrid, Spain, where she leads the GI and NE Oncology Unit. She is also an Associate Professor at Universidad Complutense in Madrid (UCM), Spain. She is a member of the ENETS Executive Committee, a member of the ESMO NET Track Scientific Committee, and the Past Chair of the Spanish National Cooperative Group of NETs (GETNE) (2011-2019). Professor Garcia-Carbonero is actively involved in clinical and translational research with a particular focus on the development of new drugs in GI and NENs. She also devotes a lot of time to continued medical education. She is a member of the ESMO Oncology PRO working group and the director of the GETNE UCM Master in NENs.
Ulrike Garske-Román is a Senior Consultant in oncology/nuclear medicine at Uppsala University Hospital, Sweden. She previously worked at the Sahlgrenska University hospital in Gothenburg from 2014 until 2020. Her special interests include dosimetry-guided radionuclide treatment of neuroendocrine tumors and nuclear medical diagnostic of oncological, endocrine and inflammatory conditions. She obtained her medical degree in 1992 from the Justus-Liebig University in Giessen, Germany, completed her MD thesis on histopathology of thymic tumors at the Philipps University in Marburg, Germany, in 1994, and her PhD thesis on 177Lu-DOTA-octreotate radionuclide therapy of neuroendocrine tumors at Uppsala University, Sweden, in 2012. She was board-certified in oncology in 1998, internal medicine in 2001, and nuclear medicine in 2005. Between 2001 and 2016, she was in charge of radionuclide therapy at the University Hospital in Uppsala.
Wanda Geilvoet is chair of the ENETS Nurse & Dietician Group and works at the Erasmus Medical Center, an ENETS Center of Excellence, in Rotterdam, the Netherlands. Since 2007 she works as a nurse practitioner in the outpatient clinic for patients with endocrine tumors, including patients with neuroendocrine tumors. She works as a patient coordinator and contact person for NET patients and their families in the NET outpatient clinic and the joint clinic for endocrinology and surgery. She is an active member of the tumor board for endocrine tumors and is closely involved with the ENETS Center of Excellence audits in her hospital. She is an active ENETS member since 2009 and an active member of the Dutch Endocrine Nurses Group (LWEV) since 2004.
Elyse Gellerman is Chief Executive Officer of the Neuroendocrine Tumor Research Foundation (NETRF) and has been at NETRF since 2016. She leads the foundation, which is the largest private funder of NET research. Ms. Gellerman is NETRF’s representative to INCA, a member of the NORD Rare Cancer Coalition, and has worked in oncology for twenty years. She was previously a Regional Vice President for Sarah Cannon, the oncology service line for Hospital Corporation of America (HCA). In 2011, she was recognised by United States President Obama‘s administration as a Champion for Change in the fight against breast cancer. Ms. Gellerman has a bachelor’s degree from Cornell University and a master’s degree from the University of Denver.
Simona Glasberg is Head of the NET Unit at Hadassah-Hebrew University Medical Center, Jerusalem, Israel, which is an ENETS Center of Excellence (CoE). She is a specialist in endocrinology and internal medicine and completed a fellowship in neuroendocrinology and endocrine oncology at St. Bartholomew’s Hospital & William Harvey Research Institute, London, UK. Dr Glasberg mainly focuses on the mechanisms by which somatostatin analogues regulate NEN growth and their interaction with mTOR inhibitors. Since returning to Israel, she continues to be actively involved in research in the field and the care of NEN patients. Established as one of the foremost experts in Israel, Simona is a member of the ENETS Advisory Board, as well as an Executive Committee of the European Society of Endocrinology (ESE) and the Israeli Endocrine Society. She is also the Scientific Chair of the Middle East Neuroendocrine Tumor Society (MENETS), the Israeli patient advocacy group. She has published extensively and presented at national and international conferences on the topic of NENs. Dr Glasberg is the recipient of the prestigious 2017 Lindner Prize of the Israel Endocrine Society in recognition of her contribution to the field of neuroendocrine neoplasms.
Enrique Grande, MD, PhD, MSc, is the Director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Cancer Center, Madrid, Spain. Dr Grande’s research focus is on genitourinary and endocrine tumors, and he actively collaborates with the development of the Translational Research and Early Drug Development Unit. Dr Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). He has authored more than 200 manuscripts in peer-reviewed journals. Dr Grande is also the Founder of the Spanish Group for Research on Orphan and Uncommon Tumours (GETHI) and member of the Directory Board at the Spanish Task Force Group for NETs (GETNE). He is editor of several international journals and has participated in the most recent trials in the field of neuroendocrine tumors that led to the approval of the new drugs we have now available in this field.
Thorvardur Halfdanarson is a medical oncologist at Mayo Clinic in Rochester, Minnesota, USA. He received his medical degree from the University of Iceland and completed a residency in Internal Medicine at the University of Iowa followed by a fellowship in Hematology and Oncology at Mayo Clinic in Rochester Minnesota. He is currently a Professor of Oncology at Mayo Clinic as well as the GI Tumor Group Chair in Medical Oncology at Mayo Clinic. Dr. Halfdanarson is on the Board of Directors and Secretary at NANETS and a Past Chair of the NANETS Guidelines Committee, a member of the NCCN NET Guidelines Panel and a NET Faculty Member at ESMO. His clinical practice and research interests are predominantly within neuroendocrine oncology.
Jacqueline (Jackie) Herman President & Director, Treatment Access & Health Policy Canadian Neuroendocrine Tumour Society (CNETS) Jackie Herman, volunteer President of CNETS, has been active in the charitable sector since 2009, following her own diagnosis with neuroendocrine cancer in 2008. Jackie is committed to ensuring the Canadian neuroendocrine cancer patient voice is heard and the mandate of CNETS is carried out. Jackie has been a strong advocate for equitable access to treatments and diagnostics in Canada. Jackie has openly shared her neuroendocrine cancer patient perspective in presentation, committee, and research work over the past 8 years and has presented at various medical and scientific meetings sharing insights and challenges of the neuroendocrine cancer patient journey.
Rodney Hicks is He has had a 30-year involvement in the diagnostic and therapeutic use of radionuclides in various neuroendocrine tumors, which started with the early involvement of the use of MIBG and evolved to the use of somatostatin analogues. He established peptide receptor radionuclide therapy at the Peter MacCallum Cancer Centre in 1996 using the high administered activity protocols of the Erasmus Medical Center. He runs a preclinical lab that focuses on novel combination therapies and development of novel imaging agents.
Hans Hofland is a Consultant Endocrinologist and clinician scientist at the Erasmus Medical Centre in Rotterdam, the Netherlands. He completed his PhD with honours on the production and effects of steroid hormones in endocrine tumors at the same insitute. This was followed by an ERC Marie-Curie Intra-European fellowship at the University of Birmingham, UK. He currently participates in specialised endocrine oncology clinics and is the medical lead for peptide receptor radionuclide therapy within the Erasmus MC, an ENETS Center of Excellence (CoE). His key research interests are translational approaches to discover novel biomarkers and improve therapeutic options for neuroendocrine tumor patients, with a particular focus on radionuclide therapy.
James Howe is Professor of Surgery and Division Director of Surgical Oncology and Endocrine Surgery at the University of Iowa, USA. He trained at Washington University and Memorial Sloan-Kettering Cancer Center. His clinical practice is in general Surgical Oncology and Endocrine Surgery with a special emphasis on small bowel NETs, pancreatic NETs, and cytoreduction of liver metastases. He is currently the Past President of the North American Neuroendocrine Tumor Society (NANETS) and President of the Society of Surgical Oncology. His basic science research is dedicated to understanding the molecular genetic basis of familial cancer syndromes, gene expression patterns in neuroendocrine tumors (NETs), and development of new therapeutics. He has written numerous clinical and basic science articles on the subject of NETs.
Mimi Hu is an endocrinologist and Professor and Deputy Chair of Clinical Affairs in the Department of Endocrinology and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Professor Hu's clinical expertise is in the evaluation and treatment of patients with thyroid carcinoma, with a special focus on medullary thyroid cancer and hereditary endocrine neoplasia disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid carcinoma. She has published articles and book chapters evaluating the management of medullary thyroid carcinoma, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders.
Gregory Kaltsas is currently a Professor of General Medicine-Endocrinology at the National and Kapodistrian University of Athens and the head of the ENETS Center of Excellence for Neuroendocrine Tumors in Athens, Greece. He was trained in general medicine-endocrinology in London, UK, where he developed a special interest in neuroendocrinology and endocrine oncology, particularly in neuroendocrine neoplasms. Professor Kaltsas is also interested in adrenal physiology and adrenal neoplasms. He is a member of the Executive Committee of International Society of Endocrinology (ISE) and of the Advisory Board of ENETS, and acts as an Associate Editor in three international scientific journals. He has published several peer-reviewed articles in the field of neuroendocrine neoplasms and acts as a reviewer for several scientific journals.
Kenta Kawasaki belongs to Keio University School of Medicine, Department of Organoid Medicine, in Tokyo, Japan. He has focused on clinical care and basic research of GEP-NEN as a medical oncologist for the past 7 years. He will talk about GEP-NEN organoid biobank, which clarified the landscape of the genetic mutation, expression profiles and the mechanism of the development of GEP-NEC from normal colon tissue through to the establishment of 25 GEP-NEN organoid lines from fresh human clinical samples.
Andreas Kjaer, MD, PhD, DMSc, MBA, is Professor at the University of Copenhagen and Chief Physician at the Dept. of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet, the National University Hospital of Denmark, Denmark. He served on the scientific board of the Danish Cancer Society, the Oncology Committee of EANM and the ENETS Advisory Board. He is founding Editor-in-Chief of Diagnostics and an international associate editor of JNM. His research focuses on molecular imaging with PET and PET/MRI in cancer, and his achievements include development of several new tracers that have reached first-in-human clinical use. He is the holder of an ERC Advanced Grant and co-ordinator of an EU H2020 project. He has published more than 500 peer-reviewed articles, supervised 40 PhD students, and has received numerous prestigious scientific awards. He is a member of the Danish Academy of Technical Sciences.
Teodora Kolarova serves as Executive Director of the International Neuroendocrine Cancer Alliance (INCA), which is an umbrella group of 26 organizations from 22 countries. INCA is the global voice in support of neuroendocrine cancer patients. Teodora has been a member of INCA’s Board of Directors and Chairperson of INCA’s Communications Committee from 2012 - 2015. She has served as INCA President from 2014 - 2015. A key priority for Teodora in her advocacy work is the development and enforcement of a sustainable collaborative model to approach cancer care with patients in the focus. Fostering meaningful relationships that last, Teodora has helped INCA gain recognition as a key partner in many international initiatives. Teodora became the first patient representative to hold a seat on the ENETS Advisory Board.
Beata Kos-Kudla currently serves as Chair of the Department of Endocrinology and Neuroendocrine Tumors at the Medical University of Silesia, Katowice, Poland. She founded Polish Network for Neuroendocrine Tumors and National NET Register. She is President Elect of the Polish Society of Endocrinology, a member of Executive Committee of the European Society of Endocrinology and of the ENETS Advisory Board, where she was also served as a member of the Executive Committee, and was an active participant in creating the European NET Register. She has published over 500 publications. Being active participant in the work of many scientific societies and organizer of numerous, scientific congresses, she is also Editor In Chief of Polish Journal of Endocrinology.
Anna Koumarianou is currently a Consultant in a Medical Oncology and Head of Hematology-Oncology Unit,Fourth Department of Internal Medicine at the "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, Greece. This unit is a partner of the LAIKO EKPA, an ENETS Center of Excellence led by Professor Gregory Kaltsas. She obtained her PhDin tumor immunotherapies from the Imperial College School of Medicine, London, UK. She is an expert in the evaluation of EU-funded programmes and is a Principal Investigator in Phase I-IV studies. She also supervises undergraduate and postgraduate students in translational research protocols. Dr Koumarianou has been member of the ENETS Advisory Board since 2019, is a member of the Scientific Committee of Hellenic Cooperative Oncology Group, is on the Board of Directors at the Hellenic Oncology Research Group and is Special Secretary of the Hellenic Society of Immuno-Oncology. She has authored more than 100 peer-reviewed articles.
Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology and Leader of the GI Cancer Program at Yale School of Medicine and Yale Cancer Center, New Haven, USA. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency and oncology fellowship at Stanford University School of Medicine. Dr Kunz specialises in the treatment of patients with gastrointestinal (GI) malignancies and neuroendocrine tumors (NETs). She has been involved with the development and conduct of numerous clinical trials in the field and will co-direct an upcoming NCI-sponsored NET Clinical Trials Planning Meeting that will set future priorities for NETs. She also holds key leadership positions in the field including Chair of the Neuroendocrine Tumor Taskforce of the NCI and officer of the NANETS.
Anna La Salvia (MD, PhD fellow) is a medical oncologist at the Gastrointestinal and Neuroendocrine Tumor Unit of the University Hospital Doce de Octubre, Madrid, Spain. She is actively involved in research activities (as sub-investigator in several phase I-II-III clinical trials, as well as in numerous translational research projects in the field of neuroendocrine tumors) and clinical activities. To date, she has published many articles in peer-reviewed journals. In 2019 she won the Junior GETNE (Grupo Español de Tumores Neuroendocrinos) research grant. Her scientific work concentrates on molecular, pathological and clinical correlations to identify predictive and prognostic factors and to personalise the treatment of patients with neuroendocrine tumors.
Angela Lamarca is a medical oncologist (MD, PhD, MSc) specialised in gastrointestinal malignancies (hepato-pancreato-biliary (HPB) and neuroendocrine tumors (NETs)). She completed her training in medical oncology (including her PhD) in Spain (Hospital Universitario La Paz, Madrid). She moved to The Christie NHS Foundation Trust (Manchester, United Kingdom) in 2013, where she completed a 4-year fellowship programme in HPB and NETs. Dr Lamarca has completed her first master’s degree in Molecular Biology of Cancer and a second master’s degree in Biostatistics. She was awarded with an American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed as a Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2018. She is currently developing her career as a clinical and translational researcher with a special interest in neuroendocrine tumors. Dr Lamarca is a member of the EORTC Gastrointestinal Cancer Group and a faculty member of the ESMO Neuroendocrine, Endocrine Neoplasms and CUP Group. She serves as a member of the ENETS Advisory Board since 2020.
Riccardo Laudicella is a Nuclear Medicine Attendant at the University Hospital of Messina, Italy. He is also a PhD-student in “Bioengineering Applied to Medical Sciences” in the University of Messina and he is a fellow in Zurich (USZ) in "hybrid imaging of genitourinary cancer and glucose metabolism". He graduated at the University of Palermo where he spent six months in the Ovidius University in Constanta (Romania) for the Erasmus project, and he completed an internship in the Radiology Department of Palermo with a bachelor thesis on “Morphovolumetric Studies in the Neuroradiological Field”. Afterwards, he completed the four-year nuclear medicine residency programme at the University of Messina with a bachelor thesis on “Applications of Radiomics on 18F-Choline PET/CT Images”. During his Residency, he spent 4 months as a visiting trainee and researcher in the Division of Nuclear Medicine and Molecular Imaging at Stanford University (2018) and in the Nuclear Medicine Unit at Giglio-S.Raffaele Hospital in Cefalù (2019). He is also the Head of the Italian Association of Young Nuclear Medicine Physician/Residents, and his main interests comprise artificial intelligence applications, nuclear medicine therapy, and PET/MR.
Côme Lepage he has been Professor of Hepato Gastroenterology at the University Hospital of Dijon, France, since 2009. Since 2012, he has been Head of the INSERM unit EPICAD LNC 1231 which is invested in clinical research and epidemiology in digestive oncology. His main interests include clinical research, and also trends in digestive cancer incidence, mortality and survival, and the application of these metrics to public-health policy and cancer control, in particular in the field of NETs. He is member of the executive board of the French NET group (www.reseau-gte.org), of Francophone Federation of Digestive Oncology (www.ffcd.fr), and of the European Society of Digestive oncology (www.esdo.eu).
Simone Leyden co-founded the Unicorn Foundation Australia in 2009 after seeing a huge disparity in treatment and support options for rare cancers (due to her sister’s diagnosis), when compared to more common cancers. In her role as CEO, Simone advocates for greater access to treatments and diagnostics, raises funds for the Neuroendocrine Tumour (NET) Nurse Support Service, funds clinical trials, produces education resources about NET cancers and raises awareness about NETs within the medical community and general public. Simone is an active member of many associations and is the current President and Research Chair of the International Neuroendocrine Cancer Alliance (INCA), which represents 26 NET member organisations around the world. Simone has been involved in and convened international medical conferences including convening the 4th World Theranostics Congress (2016) and in 2018 convened the 6th Annual Asia Pacific NET Society meeting (APNETS). Simone is passionate about cancer research, equitable access to healthcare and improving efficiencies in healthcare delivery.
Monica Marazuela is Chief of the Department of Endocrinology at Hospital La Princesa, Professor of Endocrinology at Universidad Autónoma de Madrid, Spain, and Head of the Endocrinology Research Group at the Institute of Biomedical Research Princesa, Madrid, Spain. She graduated and obtained her PhD at the Universidad Complutense de Madrid and completed her training at the London University Hospital and at Harvard Medical School in Boston, USA. Her research has been focused on the mechanisms related to immune response and in different neuroendocrine tumors, including pituitary and gastrointestinal tumors. She has published over 120 scientific articles and has been the main researcher in more than 15 grants. She serves as Secretary of the European Society of Endocrinology (ESE) and is in the Editorial Board Member of Endocrine and the Journal of Clinical Endocrinology and Metabolism.
Wendy Martin currently works as the Lead Neuroendocrine Clinical Nurse Specialist at King’s College Hospital NHS foundation Trust, UK, an ENET’s Center of Excellence (CoE). She has worked in the liver unit for 20 years, initially in the liver intensive care unit, then as a practice development nurse before joining the clinical nurse specialist team 8 years ago. Wendy’s first clinical nurse specialist role was facilitating and caring for patients undergoing radioembolisation and she has worked within the neuroendocrine service for the last 6 years. Wendy has completed her master’s degree in healthcare practice (cancer). Her areas of interest within NET are carcinoid heart disease, radioembolisation, supported self-management, and quality of life.
Emilie Mathian is a new Ph.D. candidate working at the International Agency of Research on Cancer (IARC-WHO) in Lyon, France. She is studying the lung neuroendocrine neoplasms, focusing her attention on the typical and the atypical carcinoids. Through computer vision techniques applied on FFPE H&E slides of those types of tumors, she is trying to predict their class, their survival, and the main genomic alterations. She focuses her attention on finding new histopathological features characterising a new entity of pulmonary carcinoids called supra-carcinoids.
Mark McDonnell is Treasurer of INCA and Chairperson of NET Patient Network Ireland, a NET patient support and advocacy group. With a master’s degree in Electronic Engineering, he is a self-employed software engineer and was one of the founders of NET Patient Network in 2012. Mark was diagnosed with small-bowel NETS in 2011 and is active in trying to improve supports and services for NET patients in Ireland and globally. Mark is an INCA board member and is chair of the SCAN project team.
Massimo Milione, MD, PhD. Is Chief of the 1st Anatomopathology Department at Fondazione IRCCS Istituto Nazionale Tumori in Milan, Italy. His main ongoing projects include TRANSCAN2 "translational research on rare cancers – Predictive models of therapy response in pancreatic neuroendocrine tumors” and “observational trial on the evaluation of the prognostic and predictive impact of the morphological, immunofenotypical and biological-molecular reclassification of neuroendocrine malignancy (NEN) paying particular attention to the role of immunity-based factors“. He is a member of ENETS, ESMO (European Society of Medical Oncology), USCAP (United States and Canadian Academy of Pathology), SIAPEC (Italian Society of Pathological Anatomy and Cytodiagnostics), SIGE (Italian Society of Diseases of the Digestive System), and SIED (Italian Society of Digestive Endoscopy).
Nieveen van Dijkum
Els Nieveen van Dijkum works as a surgeon at the Amsterdam UMC, an ENETs Center of Excellence and regional referral center for patients with neuroendocrine and endocrine tumors in Amsterdam, the Netherlands. Since both the academic hospitals in Amsterdam merged to become the Amsterdam UMC, all patients with endocrine and neuroendocrine tumors are treated in ACcENT, the Amsterdam Center of Endocrine and Neuroendocrine Tumors. Her research interests include pancreatic and gastrointestinal NEN as well as adrenal and thyroid tumors. She is also Director of the residency training programme and dedicates a significant amount of her time to education.
Sophie Noble was appointed to the post of Leicester Macmillan Neuroendocrine CNS, UK, in November 2018. Her previous experience was gained with NET patients during the 13 years she was HPB Clinical Nurse Specialist (CNS) in Leicester. Sophie qualified as a Registered General Nurse in 1986 from the Middlesex Hospital in London. She gained nursing experience in vascular surgery, endoscopy and general medicine, working in several different UK cities. Sophie graduated from the Open University in 1995 with a BA (Hons) in English Literature and the History of Art. Before joining the ENETS nursing advisory board in May 2019, she had been an active member on the medical advisory board to Pancreatic Cancer UK. Furthermore, for 6 years, she was the nurse representative on the committee of the Pancreatic Society of Great Britain and Ireland. On becoming the Leicester NET CNS, Sophie was required to establish the nursing service in order to support the daily management and care of the NET patients. Sophie is keen to promote the support of NET nurses in their specialist field whether through research, education or care to strive for excellence.
Dermot O’Toole is Professor of Gastroenterology and Clinical Medicine at Trinity College Dublin (TCD, The University of Dublin) and Consultant Gastroenterologist at St James’s and St. Vincent’s University Hospitals Dublin, Ireland. He graduated from TCD and has postgraduate degrees from TCD and the Universities of Paris and Angers. His major research interests include gastrointestinal cancer biology, especially in neuroendocrine tumor (NET)-related diseases and early GI neoplasia (Barrett’s oesophagus, gastric and colorectal cancers). Professor O’Toole is Clinical Lead for the national NET group. He has served on the Executive Committee of the European Neuroendocrine Tumor Society (ENETS) and is current Vice-Chairman of ENETS, helping to develop guideline papers and standards of care initiatives in the field of NET. He is Past Chair of the ENETS-driven European Centers of Excellence programme. He has been involved in many national and international research activities in GI oncology and is a member of several professional bodies in Europe and North America, serving as advisor to national health-care projects as well as patient advocacy groups.
Kjell Öberg is a Senior Professor at Dept of Medical Sciences and Senior Advisor for the Department of Endocrine Oncology at the University Hospital Uppsala, Sweden. He was formerly the Head of the Department of Endocrine Oncology and Associate Director of Ludwig institute for Cancer Research and Chairman of Department of Medical Sciences and Dean of the Medical Faculty at Uppsala University. Professor Öberg is one of the founding members of ENETS and NANETS and pioneered the diagnosis and treatment of NETs. He has more than 45 years of experience in the field, has authored more than 600 publications, and has an h-factor of 98. He has received numerous awards, including the European Interferon Research Award in 1991, the Eminent Scientist of the Year in 2003, the European Gold Medal in Endocrinology from the English Endocrine Society in 2004, the Rudbeck Medallion for Excellence in Research in 2014, the NANETS Lifetime Achievement Award in 2014, the ENETS Life Achievement Award in 2017, the Swedish Endocrine Society Gold Medal for Excellence in Research, and the Asia-Pacific Neuroendocrine Society Lifetime Achievement Award. He is a member of The Royal Society of Sciences, Finnish Oncology and Spanish Neuroendocrine Society.
Kira Oleinikov is a Senior Physician at the Neuroendocrine Tumor Unit and ENETS Center of Excellence, Endocrinology Department, Division of Medicine of the Hadassah-Hebrew University Medical Center, in Jerusalem, Israel. Her main research interests include evaluating different treatment approaches to pancreatic NETs and developing new biomarkers for lung carcinoids.
Raik Otto is a Next-Generation Sequencing (NGS) Bioinformatician by training and researcher and teacher at the Humboldt-Universität zu Berlin, belonging to the group of Ulf Leser, in Germany. His personally specialises in the combination of NGS data analysis and machine-learning techniques.
Ulrich-Frank Pape is currently Chairman of the Department of Internal Medicine and Gastroenterology at Asklepios Klinik St. Georg in Hamburg, Germany, and a research associate of the Intestinal Failure Team at the Department of Hepatology and Gastroenterology at Charité Campus Mitte, Charité University Medicine Berlin, Germany. He studied Medicine at the Free University of Berlin, Germany, between 1989 and 1997, and at New England Medical Center and Joslin Diabetes Center/Harvard Medical School in Boston, USA, in 1995/96. He holds board certifications in Internal Medicine, Gastroenterology and Emergency Medicine. Dr Pape specialises in clinical care as well as clinical and translational research of nutritional medicine, chronic intestinal failure, intestinal rehabilitation and gastrointestinal cancers particularly neuroendocrine neoplasms with a focus on gastrointestinal endocrinology. He is author and co-author of multiple publications and of several national and international short bowel and ENETS consensus papers.
Stefano Partelli is an Associate Professor at the Vita-Salute San Raffaele University and a Consultant Surgeon at the Pancreatic Surgery Unit of the San Raffaele Research Hospital in Milan, Italy, an ENETS Center of Excellence (CoE). He has authored 180 papers in peer-reviewed journals mainly focusing on pancreatic neuroendocrine tumors. He is a member of the ENETS Advisory Board since 2020.
Marianne Pavel is a Senior Physician and Chair of Endocrinology at the Friedrich-Alexander University of Erlangen, Germany. She is also Head of the NET Center. Her major focus for the last 20 years is on neuroendocrine tumors. She is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Board certified as a specialist in internal medicine in 2000, and endocrinology/diabetes in 2001, she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital in Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité in 2010. She has conducted numerous clinical trials in the field of NET and supports the activities of ENETS since 2005. In 2009, under her guidance, the NET Center at the Charité was certified as one of the first ENETS Centers of Excellence. She is a member of the ENETS Executive Committee since April 2014 and its Chair since 2020.
Marc Peeters is Professor of Oncology at the Antwerp University, Belgium. He is head of the Oncology Department at the Antwerp University Hospital and Coordinator of the Multidisciplinary Oncology Center Antwerp. He is also Chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospital in Ghent, Belgium. He completed his medical studies at the Catholic University in Leuven, Belgium. He underwent additional training in Oncology and Digestive Oncology at the UZ Gasthuisberg, the Institut Gustave Roussy in Villejuif, Paris, the University of Pennsylvania Hospital in Philadelphia, the Royal Marsden Hospital in London, and the Memorial Sloan-Kettering Cancer Center in New York. Dr Peeters is a board member of the Flemish Society of Gastroenterology, Chair of the Belgian Group of Digestive Oncology and member of the Belgian Society of Medical Oncology, the European Society of Medical Oncology, the American Society for Clinical Oncology and the gastrointestinal group of the European Organisation for Research and Treatment of Cancer. Within EORTC, he is Co-chair of the metastatic colorectal task force. His research interests include the identification of molecular markers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals, and was author of several chapters in oncology books.
Aurel Perren is Director of the Institute of Pathology at the University Bern, Switzerland, since 2009. He completed his pathology training in Zurich with a special focus on endocrine tumors. In 2007 he was appointed Professor of Pathology in the Technische Universität München, Munich, Germany. His research focus lies on the histopathological, molecular, and genetic analysis of familial and sporadic NEN with a special interest in pancreatic NEN. He was involved in the WHO classification of endocrine tumors in 2004, 2017 and 2019. Since the first Frascati meeting in 2005, Aurel Perren has been regularly involved in European Neuroendocrine Tumor Society (ENETS) activities and takes part in interdisciplinary discussions bringing pathological and genetic viewpoints to the table. He has published in numerous scientific journals and is member of the editorial boards of Endocrine Pathology, Pathobiology, Virchows Archiv, and Endocrine-Related Cancer.
Deborah Pitfield has a nursing background in medical oncology with more than 25 years of experience. Her career began in 1985, when she qualified at the Royal London Hospital, UK. Since then, she has been fortunate to have gained varied experience as an oncology research sister, a cancer information officer at BACUP, a chemotherapy nurse, and then as team lead in oncology clinical trials in Cambridge. Her current role is as NET specialist nurse at Addenbrooke's Hospital. Her chief responsibilities include caring for NET patients and those patients with hereditary endocrine neoplasia syndromes such as MEN1, SDHB gene carriers. She is also involved in the care of NET patients receiving treatment with targeted agents such as Sunitinib, PRRT and systemic chemotherapy. Addenbrooke's Hospital is in the process of applying to become ENETS Center of Excellence.
Vikas Prasad is a nuclear medicine physician and Vice Chair and Senior Physician in the Department of Nuclear Medicine, University Hospital of Ulm, Germany. Prior to that from 2011 till 2018, he was as Deputy Director of the Department of Nuclear Medicine at Charite University Hospital, Berlin, Germany. From 2006 – 2011, he was Senior Physician at the Department of Nuclear Medicine, Zentralklinik Bad Berka. His research interests and area of expertise comprise theragnostics and PET/CT. He has 15 years of experience in the field of NET.
Sara Pusceddu works at the Fondazione IRCCS Istituto Tumori Milano, Italy, since 2004, and is dedicated to researching and treating NET. She is actively involved as an expert NET oncologist in Milan at an ENETS Center of Excellence (CoE), and is the referral oncologist in the dedicated NET out-patient clinic at the same institution. She has been PI or Co-Investigator in several national and international clinical trials in this field. She is currently Advisory to the Steering Committee of the Italian Association of Neuroendocrine Tumors (IT.A.NET) and Coordinator of the IT.A.NET clinical study task force. She has contributed to the national (AIOM-ITANET) and regional (ROL Lombardy) Italian NET guidelines. She has authored more than 80 paper published in peer-reviewed international journals.
Sagar Rakshit is a second-year haematology-oncology fellow at Mayo Clinic, Rochester, USA, and passionate about thoracic oncology. He completed his medical school from All India Institute of Medical Sciences, Delhi before moving to US to complete his internal medicine residency from Cleveland Clinic, Ohio. He has published a variety of articles ranging from systematic reviews, artificial intelligence in medicine and retrospective clinical database research. He shares two US patents with his mentors on the use of machine learning in imaging analysis. His goal is to pursue a career in academic thoracic oncology with focus on translational research.
John Ramage is a Consultant Physician in Gastroenterology and Hepatology, Honorary Consultant Physician at the Institute of Liver Studies, King’s College Hospital and Lead Clinician for King’s Health Partners NET Centre which includes King’s, Guys and St Thomas’s, Kent Oncology Centre and Hampshire Hospitals, UK. Professor Ramage was previously Research Director at Hampshire Hospitals Foundation Trust and is Head Clinician for the Hampshire Collaboration for Health Research and Education. Professor Ramage trained at Portsmouth, Brighton and King’s College hospitals. He is past Treasurer and immediate past Chair of the UK and Ireland Neuroendocrine Tumour Society (UKI NETS). He is a member of the EORTC Quality of Life Group, through which he pursues research into quality of life in cancers. His main research interest is in quality of life and symptoms scores in neuroendocrine tumors of the small bowel and liver. He has written more than 100 peer-reviewed publications and was the corresponding author of the UK guidelines for NETs. He now serves on the Executive Board of ENETS.
Nicholas Reed has been a Consultant in Clinical Oncology at the Beatson Oncology Centre (BOC), Glasgow, UK, since September 1984. His clinical specialties comprise thyroid, neuroendocrine (NETs) and gynaecological cancers. In 2012 he was appointed Honorary Professor in Oncology at University of Glasgow. He was a founding member, former secretary, and later Chairman of UKINETS and more recently became a member of the ENETs Advisory Board. Professor Reed chairs the scientific abstract committee for the annual ENETS conferences. He helped to found and foster SCONET, which brings together Scottish experts in NET tumors. He had previously been a member of the EORTC Gynaecological Cancer Group (Chair 2003 - 2009), NCRI gynaecological cancer CSG and the GCIG. In his spare time, he now chairs MPEP (Molecular Pathology Evaluation Programme) and sits on 5 current IDMCs.
Rachel Riechelmann is a Medical Oncologist and Clinical Researcher in NET and GI cancers. She is currently Head of Clinical Oncology at the AC Camargo Cancer Center, Sao Paulo, Brazil, and is President of the Brazilian Gastrointestinal Tumors Group. She is also a member of the ENETS Advisory Board and Founder and Coordinator of the 1st NET Fellowship in Brazil, a clinical and research-oriented one-year programme. Her current projects include a phase II trial of tamoxifen for ER/PR positive NET, METNET study (phase II trial of metformin in NET), germline mutations in young NET patients, molecular aspects of high-grade NET, Latam real-world data on NET. She has more than 100 peer-reviewed publications. Dr Riechelmann led the publication of the first Brazilian guidelines on the diagnosis and management of NET.
Anja Rinke is currently Center Coordinator at the ENETS Center of Excellence at the University Hospital Marburg, Germany, and consultant for NEN and pancreatic cancer at the center. She studied medicine at the Philipps University Marburg between 1988 and 1995 and started her residency at the University Hospital Marburg in the Department of Gastroenterology in 1995. After her board certification for internal medicine in 2003, she specialised in gastrointestinal cancers, particularly neuroendocrine tumors. She is a member of the ENETS Advisory Board, the Advisory Board of the German NET Registry, the German Internists (BDI), the German Society for Digestive and Metabolic Diseases (DGVS) and the German working group of internists in Oncology (AIO). She wrote her habilitation thesis on „Gastroenteropancreatic neuroendocrine tumors - therapeutic and prognostic aspects“.
Philippe Ruszniewski works in the Department of Gastroenterology-Pancreatology in Beaujon Hospital, Clichy, France. He is Professor of Gastroenterology at Université de Paris and is currently Dean of Paris University Medicine Faculty since 2015. Professor Ruszniewski has been involved in NET research since the 1990s, is a founding member of ENETS, was a former ENETS Chairman, and currently serves as an Advisory Board member. He is the leader of one of the six original ENETS Centers of Excellence, which was accredited in 2008. His main topics of research include the early diagnosis of functioning and non-functioning NETs and the development of new therapeutic modalities for patients with NETs. He has been particularly involved in trials with somatostatin analogues, chemotherapy, targeted therapies, and locoregional treatments such as (chemo) embolisation. Professor Ruszniewski has authored more than 460 papers, the majority of these in the field of neuroendocrine tumors.
Anguraj Sadanandam is a Reader and Team Leader at the Institute of Cancer Research (ICR), London, UK. He is currently applying his multidisciplinary skills to integrated science of stratified medicine to understand inter- and intra-tumoral/immune heterogeneity and test precise therapies for PanNETs and other GI cancers using computational (artificial intelligence), experimental (including pre-clinical in vitro and in vivo models) and clinical (accessing clinical trial samples by developing companion diagnostics) biology. Dr Sadanandam led the research work to define transcriptome/multi-omics subtypes of PanNETS, colorectal, gastroesophageal, and breast cancers associated with prognosis and potential personalised medicine (multiple high-impact Nature Medicine, Cancer Cell, Cancer Discovery, Cell, Science and has more than 60 publications). He is a Science Ambassador for non-profit NET Cancer Foundation.
Debashis Sarker is a Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals and Reader in Experimental Oncology in the School of Cancer and Pharmaceutical Sciences at King's College London, UK. He specialises in the management of neuroendocrine, pancreatic and liver cancers with a particular focus in early phase clinical trials and translational medicine. He is the lead oncologist at King's Health Partners, an ENETS Centre of Excellence (CoE), is Chair of the UKINETS Research Committee, and a member of the UK NCRI Neuroendocrine subgroup. He is lead for Cancer Genomics at NHS South East Genomics Laboratory Hub. He graduated in medicine from the University of Liverpool and trained in medical oncology at Royal Marsden Hospital/The Institute of Cancer Research, where he completed a CRUK PhD Clinical Research Fellowship.
Jean-Yves Scoazec, MD, PhD, is currently Professor of Pathology at Université Paris Sud, France, and Head of the Department of Pathology and Laboratory Medicine in Gustave Roussy Institute, Villejuif, France, where he is also director of the “Molecular Analysis, Imaging and Modelling of Cancer” Research Unit (INSERM US23/CNRS UMS3655). He was Head of the Department of Pathology in Lyon, France, from 2000 to 2014, and Director of the Neuroendocrine Tumorigenesis INSERM team from 2007 to 2014. He is Coordinator of the French expert network for pathological diagnosis of neuroendocrine tumors (TENPath). Professor Scoazec has authored more than 600 publications and his main research interests include the cellular and molecular mechanisms of neuroendocrine tumor differentiation and progression.
Simron Singh is an Associate Professor of Medicine at the University of Toronto and Co-founder of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Centre Sunnybrook Health Sciences Centre, Toronto, Canada. In addition, he is a principal investigator and associate scientist with the Institute for Clinical Evaluative Sciences and Sunnybrook Research Institute. In 2013, Dr. Singh joined Cancer Care Ontario (CCO) as the Provincial Head, Person-Centered Care Strategy responsible for the development and execution of CCO corporate strategic priority around person-centered care. He had numerous other board and administrative roles both at a national and international level. Dr Singh is the symposium chair for the North American Neuroendocrine Tumor Society (NANETS) as well as the Co-chair of the Commonwealth Neuroendocrine Tumour Group. He is the Canadian Clinical Trial group NET disease site group Co-chair as well as a member of the European Neuroendocrine Tumor Society advisory board. He currently is the co-chair of the Neuroendocrine Advisory Committee at Cancer Care Ontario which has been able to bring PRRT and Ga-68 imaging to Ontario.
Halfdan Sorbye is Professor and Head of NET and GI section at Department of Oncology, Haukeland University Hospital, Bergen, Norway. His major research focus is on high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC), neuroendocrine tumors (NET) and metastatic colorectal cancer. He has authored 122 peer-reviewed publications and has 7,000 citations. He was part of the landmark study on Nordic NEC in 2013, which showed for the first time that high-grade gastroenteropancreatic neoplasms were a very heterogeneous group both concerning prognosis and with regard to response to chemotherapy. Professor Sorbye is a member of the ENETS Advisory Board, and a faculty member for endocrine tumors and gastro-intestinal tumors for ESMO (European Society of Medical Oncology).
Raj Srirajaskanthan is the clinical lead for gastroenterology at King’s College Hospital, London, UK. He is also a Reader of Gastroenterology at King’s College London. He is head of the King’s Health Partners and affiliated centers, an ENETS Center of Excellence. His specialist interests include neuroendocrine tumors and endoscopy. He is deputy director of the King’s College bowel cancer screening programme. His research programme is focused on developing ex-vivo models of NENs, as well as the gastrointestinal consequences of NENs. He is Chairman of the UKI NETS clinical practice committee and a member of the gastroduodenal society of the BSG.
Anders Sundin is Professor of Clinical PET at Uppsala University and senior consultant at the Department of Radiology & Molecular Imaging, Uppsala University Hospital, Sweden. His clinical work and research focus on oncological imaging, especially endocrine and neuroendocrine imaging mainly with CT, MRI, PET/CT, PET/MRI and SPECT/CT. As a past member of the ENETS Advisory Board, he has participated in developing guidelines, including those for radiological and nuclear medicine imaging. He had also participated in writing the EANM and Nordic NET guidelines. Professor Sundin has published approximately 200 scientific papers, reviews and book chapters, mainly on oncological imaging and particularly on nuclear medicine and radiological imaging of endocrine and neuroendocrine tumors and on PRRT.
Chrissie Thirlwell is a Professor of Cancer Genomics at University of Exeter Medical School, UK. She has an international reputation for research into and on the management of neuroendocrine tumors and integrated genomic analyses of cancer. She is a UKI NETs Executive and ENETs Advisory Board member and sits on the NETRF (USA) board of scientific advisors. Her research group has focused on integrated genomic and circulating free DNA analysis in neuroendocrine and other solid tumors. Professor Thirlwell chairs the Genomics England Neuroendocrine Tumour 100,000 Genomes Clinical Interpretation group (GeCIP) and is the Cancer Arm representative on the 100,000 genomes GeCIP board. She is also a member of a Genomics England working group working towards the delivery and impact of the next 5 million genomes.
Eva Tiensuu Janson serves as a Senior Consultant at the ENETS CoE in Uppsala. She is a Professor of Medicine at the Department of Medical Sciences, Uppsala University, Sweden. Since 2020 she is Deputy Vice-rector of the disciplinary domain of Medicine and Pharmacy at Uppsala University. Professor Janson is Chair of the Nordic Neuroendocrine Tumor Group and member of the Executive Committee of the ENETS. Her translational research has resulted in more than 100 publications in peer-reviewed journals; she focuses on the genetics and tumor biology of neuroendocrine tumors. She chairs the Swedish national registry as well as the committee for the national caring programme for gastrointestinal neuroendocrine tumors.
Christos Toumpanakis, MD, PhD, FRCP, AGAF, FEBGH, is a Consultant in Gastroenterology & NET at the NET Unit (ENETS Center of Excellence) of Royal Free Hospital, London, UK. He is also an Honorary Associate Professor at University College of London and has been awarded “Top-Teacher” of the Year seven times. He is the Chair of ENETS Advisory Board, Co-chair of ENETS Postgraduate Course, co-editor of the ENETS CME programme and co-author of UKINETS & ENETS Guidelines. He has presented at several national and international conferences and published many original papers and reviews. He leads a NET clinical research group and his main research interests include novel NET biomarkers, molecular imaging in NETs, and carcinoid heart disease.
Gerlof D Valk, M.D., Ph.D., is Professor of Endocrinology at the University Medical Center Utrecht, the Netherlands, an ENETS Center of Excellence (CoE) and ERN Reference Center. In his clinical activities he focuses on endocrinology, hereditary endocrine tumor syndromes, and endocrine oncology. His area of expertise comprises the diagnosis of (neuro-)endocrine tumors, its treatment and follow-up, care for patients with MEN, and the standardisation and continuous improvement of the (inter-)national care for patients with MEN. Professor Valk has initiated the national longitudinal Dutch MEN database which includes clinical data and biobank material of over 90% of the Dutch MEN patients, and he leads the Dutch MEN study group. His main research focuses on epidemiological and translational research within the field of MEN related (pancreatic) neuroendocrine tumors, including innovative treatment strategies and personalised patient care. Patient advocacy groups are actively involved in his clinical and research activities. He was appointed national coordinator for rare endocrine conditions in the Netherlands by the Dutch Endocrine Society (NVE) – the aim of this role is to embed national expert centers appointed within the European Reference Networks (ERNs) in day-to-day healthcare from the patients’ perspective. He is Chairman of the tumor board committee of the UMC Utrecht Cancer Center.
Juan Valle is a Professor of Medical Oncology in the University of Manchester, UK. His clinical practice is based at The Christie NHS Foundation Trust. In addition to NETs, he also treats cancers of the pancreas, liver and biliary tract. Professor Valle has been awarded a number of grants for research leading to a number of high-impact, practice-changing publications and presentations at national and international meetings. He is a peer reviewer for numerous international medical journals and grant-awarding bodies. Professor Valle co-led the establishment of The Christie Neuroendocrine European Neuroendocrine Tumour Society, an ENETS Center of Excellence (CoE) in Manchester in 2011, and currently sits on the ENETS Advisory Board. He previously chaired the UK National Cancer Research Institute (NCRI) neuroendocrine subgroup (2013 – 2017). Professor Valle is Co-chair of the EORTC Hepatobiliary Task Force, which also includes NETs. He is also a member of ASCO (American Society of Clinical Oncology), ESMO (European Society of Medical Oncology), and UKI NETS (UK and Ireland Neuroendocrine Tumour Society).
Timon Vandamme is a Consultant in digestive and neuroendocrine oncology at the University Hospital Antwerp, Belgium. He obtained a joint PhD at the University of Antwerp, Belgium, and the Erasmus MC, Rotterdam, the Netherlands, on everolimus resistance and pancreatic neuroendocrine tumor genomics. His research has led to multiple publications in peer-reviewed journals. During his PhD, he was involved in setting up NETwerk, the first European Neuroendocrine Tumor Society (ENETS) Network of Excellence in Antwerp, Belgium. Currently, he serves as NETwerk coordinator. He presented his research at various national and international conferences, including three oral presentations at ENETS. His research won different awards, including the ENETS-Ipsen Translational Research Fellowship in 2013.
Chris Verslype is Professor of Medicine at K.U.Leuven, Belgium, and digestive oncologist in the University Hospital Leuven, Belgium. He obtained his MD in 1992 and a PhD in 2002 at the University of Leuven. Since 2000, he has held staff positions in the Department of Hepatology and the Department of Digestive Oncology at the University Hospitals Leuven. He is Vice Dean for International Affairs at the Faculty of Medicine (K.U.Leuven) since 2016. His research focuses on the pathogenesis, diagnosis and treatment of hepatobiliary and neuroendocrine tumors, and he coordinates the Leuven ENETS Center of Excellence. He has (co)-authored more than 229 manuscripts in peer-reviewed journals.
Marco Volante is a Full Professor in Pathology at the University of Turin, and Director of the Pathology Unit at San Luigi Hospital, Orbassano, Turin, Italy. He completed a PhD programme in Human Oncology at University of Turin in 1998 and was a research fellow at the University of Zurich, Switzerland, from July to December in 1999. Professor Volante has held more than 100 lectures in national and international meetings and courses. He is an editorial board member of “Pathology Research International”, “Analytical and Quantitative Cytopathology and Histopathology”; "Cancers", "Frontiers Section Pathology" and “Endocrine Pathology”. He has authored more than 200 publications (Hc index: 43) and 15 book chapters. He has contributed to the WHO classifications of Tumors of Endocrine Organs in 2004 and 2017, and of Pediatric Tumors in 2020. He was granted the international award for publishing excellence in the Journal of Clinical Endocrinology and Metabolisms for the paper JCEM 96:2146-2153, 2011. He was President of the Endocrine Pathology Society, an USCAP affiliate in 2016.
Marie-Pierre Vullierme is Associate Professor at Université Paris Diderot-Paris 7, Université de Paris, INSERM U1149 CRB3, Paris, France. She obtained her MD in 1987 and from 1984 to 1989 was resident in radiology in Paris. She works at Beaujon University Hospital, Division Department of Radiology since 1989 and focused on abdominal imaging - particularly on pancreatic imaging. For many years she has been the principal correspondent for Professor Ruszniewski’s team. She is a member of the ENETS Advisory Board since 2006. Her major research topics include PanIN, IPMN and pancreatic neuroendocrine tumors, including diagnosis, follow-up, treatment (MDCT, MRI, interventional radiology). She has published in numerous scientific journals. She is part of the editorial board of European Radiology and was also solicited for reviewing papers in Neuroendocrinology, Pancreatology, European Journal of Gastroenterology & Hepatology, and Abdominal Imaging.
Thomas Walter, MD, PhD, is a Professor of gastroenterology and works in digestive oncology at Hospices Civils de Lyon (ENETS Center of Excellence), Lyon, France. He is the scientific coordinator of the French Network of Endocrine Tumours (GTE). Professor Walter also leads a translational research lab focused on NETs. He completed his PhD at the university of Lyon. He served a fellowship in medical oncology at the University of Toronto-Princess Margaret Hospital, Canada. His main field of interests comprise gastroenteropancreatic neuroendocrine tumors (GEP-NET) and lung carcinoid tumors. He is involved in many subjects, including prognostics stratification, systemic treatments, and biomarkers. Professor Walter has gained experience as a principal coordinator of phase II trials (EVACEL, NIPINEC, MGMT-NET, BEVANEC). His work has appeared in more than 140 peer-reviewed publications.
Damian Wild was appointed Head and Professor of Nuclear Medicine by the University Hospital Basel, Switzerland, in 2012. Since 2014 he is also the Head of the Center of Nueorendocine- and Endocrine Tumors at the University Hospital Basel which is a ENETS Center of Excellence (CoE). He received his M.D. from the University of Basel in 2004 and completed his training in Nuclear Medicine in 2007. He completed his Ph.D. in 2011 at the Institute of Nuclear Medicine, University College London, UK. His main research interests are the development and clinical translation of novel radiotracers in the field of oncology especially neuroendocrine tumors. He has published more than 80 papers in peer-reviewed journals.
Jerome Zacks is a cardiologist and member of the voluntary faculty of the Icahn Medical School at Mt Sinai in New York City, New York, USA since 1979. Over the last years, Dr Zacks has specialised in Carcinoid Heart Disease which started when Richard RP Warner, MD, first asked him to help care for patients afflicted with this disease. At the time, Dr Zacks did not know much about the disease and was told that he would soon learn. Since then, he has enjoyed serving on the ENETS guidelines committee for Carcinoid Heart Disease and the NANETS guidelines committee for midgut neuroendocrine tumors. He currently spends the majority of his time caring for NET patients and teaching medical students and residents.